Today, the Food and Drug Administration approved Opill – the first-ever daily oral contraceptive approved in the U.S. to prevent pregnancy without a prescription. Perrigo, which sought FDA approval for an over-the-counter version last summer after the Supreme Court's ruling the overturned Roe v. Wade, expects to start shipping the mini pill early next year.

In May, Ireland-based Perrigo, a leading provider of consumer self-care products, gained a key recommendation from U.S. regulatory advisors, which paved the way for Opill to get clearance to be sold without a prescription. The FDA is not required to follow the advisers' recommendations, but often does.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Health Care Reform
Employee Participation
Employee-Paid